Tag Archives: NASDAQ:SAVA

Cassava Sciences (SAVA) Gets a Hold Rating from Maxim Group

Maxim Group analyst Jason McCarthy maintained a Hold rating on Cassava Sciences (SAVA – Research Report) on June 5. The company’s shares closed last Friday at $2.59, close to its 52-week low of $1.03. According to TipRanks.com, McCarthy is a

Cassava Sciences (SAVA) Receives a Buy from H.C. Wainwright

In a report released today, Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on Cassava Sciences (SAVA – Research Report), with a price target of $16.00. The company’s shares closed last Thursday at $7.81. According to TipRanks.com, Bernardino is

A Director at Cassava Sciences (NASDAQ: SAVA) is Buying Shares

Yesterday, a Director at Cassava Sciences (SAVA – Research Report), Sanford Robertson, bought shares of SAVA for $141.8K. Following this transaction Sanford Robertson’s holding in the company was increased by 46.86% to a total of $401.2K. Following Sanford Robertson’s last

Cassava Sciences (SAVA) Gets a Buy Rating from H.C. Wainwright

In a report issued on December 6, Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on Cassava Sciences (SAVA – Research Report), with a price target of $6.00. The company’s shares closed last Monday at $1.79. According to TipRanks.com,

Maxim Group Reaffirms Their Buy Rating on Cassava Sciences Inc (SAVA)

Maxim Group analyst Jason McCarthy maintained a Buy rating on Cassava Sciences Inc (SAVA – Research Report) yesterday and set a price target of $3. The company’s shares closed last Monday at $1.30. McCarthy wrote: “Cassava announced the initiation of

Analysts Offer Insights on Healthcare Companies: Cassava Sciences Inc (NASDAQ: SAVA), Palatin Technologies Inc (NYSE MKT: PTN) and Sarepta Therapeutics (NASDAQ: SRPT)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cassava Sciences Inc (SAVA – Research Report), Palatin Technologies Inc (PTN – Research Report) and Sarepta Therapeutics (SRPT – Research Report) with